LFCR vs. OMER, RIGL, SKYE, OGI, ATOS, VACC, NCNA, ZVRA, GBIO, and ME
Should you be buying Lifecore Biomedical stock or one of its competitors? The main competitors of Lifecore Biomedical include Omeros (OMER), Rigel Pharmaceuticals (RIGL), Skye Bioscience (SKYE), Organigram (OGI), Atossa Therapeutics (ATOS), Vaccitech (VACC), NuCana (NCNA), Zevra Therapeutics (ZVRA), Generation Bio (GBIO), and 23andMe (ME). These companies are all part of the "pharmaceutical preparations" industry.
Lifecore Biomedical (NASDAQ:LFCR) and Omeros (NASDAQ:OMER) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, media sentiment, profitability, institutional ownership, community ranking, valuation and earnings.
Lifecore Biomedical has a beta of 1.03, suggesting that its stock price is 3% more volatile than the S&P 500. Comparatively, Omeros has a beta of 1.34, suggesting that its stock price is 34% more volatile than the S&P 500.
In the previous week, Lifecore Biomedical had 5 more articles in the media than Omeros. MarketBeat recorded 5 mentions for Lifecore Biomedical and 0 mentions for Omeros. Omeros' average media sentiment score of 0.26 beat Lifecore Biomedical's score of 0.06 indicating that Omeros is being referred to more favorably in the news media.
Omeros received 740 more outperform votes than Lifecore Biomedical when rated by MarketBeat users. Likewise, 71.80% of users gave Omeros an outperform vote while only 12.50% of users gave Lifecore Biomedical an outperform vote.
Lifecore Biomedical has higher revenue and earnings than Omeros. Lifecore Biomedical is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks.
Lifecore Biomedical presently has a consensus target price of $9.50, indicating a potential upside of 43.07%. Given Lifecore Biomedical's stronger consensus rating and higher possible upside, research analysts clearly believe Lifecore Biomedical is more favorable than Omeros.
83.4% of Lifecore Biomedical shares are owned by institutional investors. Comparatively, 48.8% of Omeros shares are owned by institutional investors. 14.6% of Lifecore Biomedical shares are owned by insiders. Comparatively, 10.9% of Omeros shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Lifecore Biomedical's return on equity of 0.00% beat Omeros' return on equity.
Summary
Lifecore Biomedical beats Omeros on 10 of the 16 factors compared between the two stocks.
Get Lifecore Biomedical News Delivered to You Automatically
Sign up to receive the latest news and ratings for LFCR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LFCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lifecore Biomedical Competitors List
Related Companies and Tools
